LATEST BLOG

Biotech Data Calculator

JT001

05-Dec-2017 16:49 PM

1

200

     Biotechnology stock there are thousand of companies running many different clinical trial from phase 1, 2, and 3.  For some companies, these trial can make it or break it when they report their data readout, for investors, it's the love in anticipation for readout, we all want them to succeed, but that's not the case with biotech stock. Unfortunately, there are more failure than success.  Even with the utmost thorough due diligence you can be wrong and that mean your investment will take a big hit. How can you prevent this?

     Fortunately,  we have keep tracked of many clinical data readout over the years and came up with the "Biotech data calculator". This biotech calculator used a unique mathematical formula and has 82% accuracy calculating if the trial will fail or success. It's easy to use with three required field area:

  • What phase (2 or 3)? We only track 2 or 3 because they impact the stock move the most.
  • Then select the disease area, if you don't know you can easily identify by reading the company profile or look at their pipeline. There are 17 diseases you can select from the drop down menu.
  • The last step is to look at company current Market Capitalization, input from the 3 ranges in the drop down menu.  Here is full explanation https://www.tradersfish.com/Biotechnology_formula

Recently, there was three biotech companies reported data readout, by using the #BiotechCalculator  ahead of trial readout, it has predicted 4 out of 4 right. Here are the past result: EARS,  ARDX, CYTK, and SAGE (data was success as predicted)

These are the next biotech upcoming data, we run the speculation result:  AVXL, CNCE,  EYEG, FGEN,  RVNC

1. Anavex Life Sciences Corp (AVXL:NASDAQ)

Ticker: AVXL

Phase: 2

Disease Area: Alzheimer

Market Cap: $1M-$299M

Speculation result 

   

  2. Concert Pharmaceuticals Inc (CNCE:NASDAQ)

Ticker: CNCE

Phase: 2

Disease Area: Autoimmune

Market Capitalization: $300M-$999M

Speculation result 

      3. EyeGate Pharmaceuticals Inc (EYEG:NASDAQ)

Ticker: EYEG

Phase: 3

Disease Area: Opthalmonology

Market Cap: $1M-$299M

Speculation result 

 

    4. FibroGen Inc (FGEN:NASDAQ)

Ticker: FGEN

Phase: 2

Disease Area: Gastroenterology

Market Cap: $1B and above

Speculation result 

 

      5. Revance Therapeutics Inc (RVNC:NASDAQ)

Ticker: RVNC

Phase: 3

Disease Area: Other

Market Cap: $300M-$999M

Speculation result 

Disclaimers: This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com and/ or its parent company will not be held responsible and accountable for any losses you may incur using TFBSS. Please consult your own financial adviser before executing trades. 

 

Comments


Image

Ng896

05-Dec-2017 08:44 AM

$RVNC success data just as the calculator predicted. I'm taking my profits to the bank. This calculator is awesome! Thanks you, thank you.

Add Your Comment



Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.